1. 2502 TAK-385, an oral GnRH antagonist: efficacy and safety results from a randomized phase 2 trial in prostate cancer patients (pts). (September 2015) Authors: Shore, N.; Bailen, J.; Pieczonka, C.; MacLean, D.; Shi, H.; Faessel, H.; Saad, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S474 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗